Enhanced Patient Management.
Understanding how your patient is responding to treatment is important. Is their visual function improving? Is their disease progressing? Diopsys® ffERG (full field electroretinography) vision tests provide you with objective information on retinal function. These test results may be used to indicate the level of functional loss and recovery on patients with retinopathies,1 and give you the added ability to measure the effect of retinopathies on vision through the presence of cataracts.2 3 This may be particularly helpful in managing patient expectations prior to IOL procedures.
- Objectively measure functional loss and recovery1
- Enhanced treatment tracking and disease management
- Clear, intuitive report interpretation
Full Field (Flash) Electroretinography (ffERG) Vision Testing
ffERG has been recognized as an effective test in helping to diagnose and manage disease including diabetic retinopathy and central retinal vein occlusions, among others.4 5 It has also been shown to help in in cases of media opacities sufficiently dense to prevent a clear image being projected onto the retina.3
Expand sections to view resources.
There are no resources of this type for this product.
- Ventura et al. Progressive loss of retinal ganglion cell function is hindered with IOP-lowering treatment in early glaucoma. Invest Ophthalmol Vis Sci. 2012 Feb 13;53(2):659-63
- Ratanapakorn, T, et al. Effect of cataract on electroretinographic response. J Med Assoc Thai. 2010 Oct;93(10):1196-9.
- Visual Electrodiagnostics: A Guide To Procedures. International Society for Clinical Electrophysiology of Vision (ISCEV Publications) Web. 17 Jan. 2017.
- Pescosolido N, et al. Role of Electrophysiology in the Early Diagnosis and Follow-Up of Diabetic Retinopathy. Journal of Diabetes Research. 2015; http://dx.doi.org/10.1155/2015/319692
- Yasuda S, et al. Significant Correlation between Electroretinogram Parameters and Ocular Vascular Endothelial Growth Factor Concentration in Central Retinal Vein Occlusion Eyes. Invest Ophthalmol Vis Sci. 2011;52:5737–5742.
In my 40 some years in this business, this is the first time that we’ve been able to get real, objective evidence of how the retina’s doing in a host of conditions.